BCL-2 represents a major apoptosis escape mechanism in chronic lymphocytic leukaemia (CLL), allowing the leukaemic cells to evade normal processes that lead to programmed cell death. Venetoclax is a selective inhibitor of BCL-2 and as such has the potential to restore apoptotic mechanisms. In a phase Ib study, presented at EHA 2015, the chemotherapy-free combination of venetoclax and rituximab was evaluated in 49 patients with relapsed CLL.

(BELG J HEMATOL 2015;6(3):98)